恩替卡韦或替诺福韦联合PEG-IFNα-2b对经治慢性乙型肝炎低病毒血症患者的疗效

肝脏 ›› 2023, Vol. 28 ›› Issue (8): 947-949.

恩替卡韦或替诺福韦联合PEG-IFNα-2b对经治慢性乙型肝炎低病毒血症患者的疗效

张培源, 雷雪, 王美玉

163453 黑龙江大庆龙南医院(齐齐哈尔医学院第五附属医院)临床药学科

收稿日期:2023-04-28 出版日期:2023-08-31 发布日期:2023-09-21
基金资助:
黑龙江省卫生计生委科研课题(2017-444)

Therapeutic effect of entecavir or tenofovir combined with PEG-IFN α-2b on patients with chronic hepatitis B hypoviremia

ZHANG Pei-yuan, LEI Xue, WANG Mei-yu

Department of Clinical Pharmacy, Daqing Longnan Hospital (The Fifth Affiliated Hospital of Qiqihar Medical College), Heilongjiang 163453, China

Received:2023-04-28 Online:2023-08-31 Published:2023-09-21

摘要/Abstract

摘要： 目的探讨恩替卡韦或替诺福韦联合PEG-IFNα-2b对经治慢性乙型肝炎低病毒血症患者的疗效。方法选取2017年9月～2021年10月慢性乙型肝炎且未接受过抗病毒治疗患者52例,采用恩替卡韦或替诺福韦联合PEG-IFNα-2b治疗48周,比较恩替卡韦治疗组和替诺福韦治疗组患者基线特征、血细胞变化情况以及病毒学变化情况。结果二组患者基线特征无显著差异。两组患者红细胞计数、淋巴细胞计数及中性粒细胞计数均呈下降趋势,但差异无统计学意义。在治疗第48周时,替诺福韦治疗组HBeAg阴转率和HBV DNA阴转率分别为46.2%(12/26)和84.6%(22/26),显著高于恩替卡韦治疗组的11.5%(3/26)和57.7%(15/26),P<0.05。结论 HBeAg阳性的慢性乙型肝炎患者在单独使用PEG-IFNα-2b 12周后,联合使用替诺福韦的疗效优于联合使用恩替卡韦。

关键词: 慢性乙型肝炎, 恩替卡韦, 替诺福韦

Abstract: Objective To explore the effect of entecavir or tenofovir combined with PEG-IFN α-2b on treating patients with chronic hepatitis B hypoviremia.Methods From September 2017 to October 2021, 52 patients with chronic hepatitis B who had not previously received antiviral therapy were treated with entecavir or tenofovir combined with PEG-IFN α-2b for 48 weeks. The researchers compared the baseline characteristics, blood cell changes and virological changes of patients in entecavir group and tenofovir group.Results There were no significant differences between the two groups at baseline. Red blood cell count, lymphocyte count and neutrophil count showed a downward trend , but there was no significant difference between the two groups. At the 48th week of treatment, the negative conversion rates of HBeAg and HBV DNA in tenofovir group were 46.2% (12/26) and 84.6% (22/26), which were significantly higher than those of entecavir group [11.5% (3/26) and 57.7% (15/26) (P<0.05)].Conclusion In patients with HBeAg-positive chronic hepatitis B, treatment with tenofovir combined with PEG-IFN α-2b was better than treatment with entecavir combined with PEG-IFN α-2b after using PEG-IFN α-2b alone for 12 weeks.

Key words: Chronic hepatitis B, Entecavir, Tenofovir

张培源, 雷雪, 王美玉. 恩替卡韦或替诺福韦联合PEG-IFNα-2b对经治慢性乙型肝炎低病毒血症患者的疗效[J]. 肝脏, 2023, 28(8): 947-949.

ZHANG Pei-yuan, LEI Xue, WANG Mei-yu. Therapeutic effect of entecavir or tenofovir combined with PEG-IFN α-2b on patients with chronic hepatitis B hypoviremia[J]. Chinese Hepatolgy, 2023, 28(8): 947-949.

参考文献

[1] Zheng SM, Lin N, Tang SH, et al. Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: a case report and review of the literature. World J Clin Cases, 2021, 9(30): 9310-9319.
[2] Hur MH, Park MK, Cheuk-Fung Yip T, et al. Personalized antiviral drug selection in chronic hepatitis B patients using a machine learning model: a multinational study. Am J Gastroenterol, 2023.
[3] Matsui M, Asai A, Ushiro K, et al. Hb surface antigen level as a useful predictor for the treatment response to tenofovir alafenamide in nucleoside analogue naive chronic hepatitis B. In Vivo, 2023, 37(2): 726-733.
[4] Li MY, Li TT, Li KJ, et al. Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis. World J Clin Cases, 2023, 11(5): 1009-1018.
[5] Liu R, Yang L, Jiang T, et al. Hepatitis b core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic hbv infection after short-course antiviral therapy. Virulence, 2023, 14(1): 2186335.
[6] Jang TY. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues. Aliment Pharmacol Ther, 2023, 57(5): 587-588.
[7] Li YJ, Chen EQ. Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues. Aliment Pharmacol Ther, 2023, 57(5): 581-582.
[8] Zhang Q, Liu X, Pang X, et al. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis b surface antigen levels. Cytokine, 2023, 164: 156140.
[9] Wagner J, Littlejohn M, Revill PA. Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues-authors' reply. Aliment Pharmacol Ther, 2023, 57(5): 583-584.
[10] Nardone A, Nerlander L, Duffell E, et al. A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three european countries, 2019. Euro Surveill, 2023, 28(6).
[11] Lin Y, Shen G, Xie S, et al. Dynamic changes of the proportion of hla-dr and cd38 coexpression subsets on t lymphocytes during ifn-based chronic hepatitis B treatment. Front Immunol, 2022, 13: 1116160.

[1]	孙鸿展, 王欣茹, 肖丽, 薛荣荣, 咸建春. 《慢性乙型肝炎防治指南(2022年版)》及解读等两个问题的讨论[J]. 肝脏, 2023, 28(8): 885-886.
[2]	梁红妍, 申笙, 孙剑. 靶向cccDNA以实现慢性乙型肝炎治愈[J]. 肝脏, 2023, 28(8): 887-888.
[3]	张家齐, 王再超, 杨家耀, 王晓梦, 赵玉. 慢性乙型肝炎肝硬化患者继发肝性脑病风险预测模型的构建与验证[J]. 肝脏, 2023, 28(8): 916-920.
[4]	张明明, 汪艳. 线粒体应激参与慢性乙型肝炎肝损伤的机制研究[J]. 肝脏, 2023, 28(7): 743-745.
[5]	赵心怡, 孙杰, 徐炜新. 血清Maresin-1水平变化对非酒精性脂肪性肝病的影响[J]. 肝脏, 2023, 28(7): 806-809.
[6]	安宝燕, 郭清, 冯明洋, 徐玉敏, 蔡伟, 谢青, 王晖. 恩替卡韦联合卡维地洛治疗乙型肝炎肝硬化合并食管胃底静脉曲张的疗效[J]. 肝脏, 2023, 28(6): 646-648.
[7]	李芬, 韦淑珍, 李良, 莫雨灵, 傅小凡, 雷任国, 郑子玉. HBV携带孕妇妊娠期及产后肝炎发作风险及NAs干预观察[J]. 肝脏, 2023, 28(5): 527-529.
[8]	薛荣荣, 赵川, 段庆宁, 肖丽, 咸建春. 关于《慢性乙型肝炎防治指南(2022 年版)》“儿童患者”抗病毒治疗相关建议的拙见[J]. 肝脏, 2023, 28(4): 403-404.
[9]	杨梅, 吕运海. 慢性乙型肝炎抗病毒治疗过程中临床终点事件精准预测体系的建立[J]. 肝脏, 2023, 28(4): 423-427.
[10]	曹晶晶, 李荣, 李晶, 潘峰. 核苷(酸)类似物对ALT正常或轻度升高的HBeAg阴性慢性乙型肝炎患者的疗效分析[J]. 肝脏, 2023, 28(4): 432-435.
[11]	陈维华, 田玲蓉, 席祯. 长期抗病毒治疗的慢性乙型肝炎患者病情进展影响因素初探[J]. 肝脏, 2023, 28(4): 436-439.
[12]	李桂馨, 周召, 吴丽丽, 高志良, 鲁凤民. 论慢性乙型肝炎临床治愈[J]. 肝脏, 2023, 28(3): 269-272.
[13]	梁蘅恺, 韦璐, 苏明华, 梁焕, 胡伯斌, 黄建芳, 陈艳红, 江建宁. 高病毒载量慢性乙型肝炎孕妇口服核苷(酸)类抗病毒药母婴阻断的有效性和安全性[J]. 肝脏, 2023, 28(3): 296-298.
[14]	苏佩华, 魏梦平, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病对肝细胞癌发生及全因死亡影响的meta分析[J]. 肝脏, 2023, 28(3): 299-304.
[15]	解双双, 程文瑾, 焦军霞, 刘晓艳, 刘莉. 核苷(酸)经治慢性乙型肝炎患者骨质下降危险因素分析[J]. 肝脏, 2023, 28(3): 309-312.